🇺🇸 FDA
Patent

US 9487556

Polyconjugates for delivery of RNAi triggers to tumor cells in vivo

granted A61KA61K31/713A61P

Quick answer

US patent 9487556 (Polyconjugates for delivery of RNAi triggers to tumor cells in vivo) held by Arrowhead Pharmaceuticals, Inc. expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/713, A61P, A61P35/00, A61P43/00